Therapeutic Proposals That Improve Morphological Changes Of 5-Fluorouracil-Induced Intestinal Mucositis: a Review of the Literature

Maria Lucianny Lima Barbosa,¹ Lorena Lopes Brito,² Bárbara Barbosa Pires,³ Joselane Maria da Silva,⁴ João Antônio Leal de Miranda,⁴ Gilberto Santos Cerqueira¹

¹Universidade Federal do Ceará, Fortaleza, CE, Brazil
²Universidade Estadual do Ceará, Fortaleza, CE, Brazil
³Faculdade de medicina São Lucas, Porto Velho, RO, Brazil
⁴Universidade Federal do Piauí, Teresina, PI, Brazil

Disclose and conflicts of interest: none to be declared by all authors

ABSTRACT

Introduction: In this study, we aimed to perform a literature review to investigate the existence of therapeutic proposals in 5-Fluorouracil-induced intestinal mucositis, which is a common side effect of chemotherapy treatment. The literature review was performed using PubMed, Science Direct, and Bireme between 2015 and 2019. The descriptors used “intestinal mucositis” AND “intestinal mucositis and 5-Fluorouracil”. We excluded from the review studies, double data studies, titles and/or summaries that did not address therapeutic proposals, and articles not available in full. Were selected thirty-two articles, which had the objective of evaluating the effect of substances on the model of intestinal mucositis induced by 5-Fluorouracil; it is emphasized that no articles with clinical evaluation were found. On the other hand, several animal studies are being carried out with the main objective being the evaluation of probiotics, products of natural origin, and drug repurposing for the treatment of intestinal mucositis. The main morphological parameters evaluated were histological changes, inflammatory parameters, oxidative stress, intestinal permeability, microbiota homeostasis, cell apoptosis, and the number of goblet cells that are altered during the pathophysiology of intestinal mucositis. It was verified that there is still no evidence in the literature for the existence of effective clinical treatment for intestinal mucositis induced by 5-Fluorouracil. However, promising preclinical results were found with extracts of traditional plants, substances isolated from plants, and probiotics with emphasis on those of the genus Lactobacillus.

Keywords: Intestinal mucositis; Treatment; Probiotics; Plants; Drugs.

Introduction

Cancer is currently one of the most prevalent diseases worldwide. It is of great epidemiological importance, since its risk factors are highly varied and related to morbidity and mortality. The number of new cases of cancer has increased, and in 2017 there were 24.5 million cancer cases worldwide. Conversely, therapy for this disease includes several complications that depend on tumor location, malignancy, staging, and treatment modality¹.²

Surgery, radiation, chemotherapy, targeted treatments, and immunotherapy, separately or in combination, are commonly used to treat cancer. However, chemotherapy can be cited as one of the most used. It is used to eradicate malignant cells and to inhibit or prevent the growth and spread of these cells³. 5-Fluorouracil (5-FU) is a chemotherapeutic agent, and of its main side effects mucositis is the most common¹५.⁵

Mucositis is a resultant complex condition of inflammation of the oral or intestinal mucosa by the action of chemotherapeutic drugs or ionizing radiation, and it is one of the most significant side effects in the treatment of cancers. It is known as oral mucositis or intestinal mucosis, depending on the inflammation area⁶.⁷.

Intestinal mucositis results in villous atrophy, ulceration, and loss of intestinal barrier function. Mucositis can also lead intestinal basal substances to apoptosis due to their toxicity to intestinal tissue cell renewal. This biological mechanism makes patients suffer from nausea, vomiting, diarrhea, pain, weight loss, and need for enteral or parenteral nutrition. It may also lead to malnutrition and electrolyte imbalance, resulting in an increased risk of sepsis and death⁸.⁹. ¹⁰. ¹¹.

Effective therapy for this clinical condition does not yet exist, so prevention and control of mucositis symptoms are of paramount importance to avoid reducing the patient's motivation to proceed with the treatment plan and possibly compromise local control of the mucositis tumor and decrease survival rates⁸.¹₂.

Thus, the present work intends to investigate the state of the art regarding the therapeutic proposals for 5-FU-induced intestinal mucositis, through a literature review.
Materials and Methods

In this review, we searched for articles indexed in PubMed, ScienceDirect, and Bireme electronic databases, published in English, from 2015 to 2021. The review was restricted to articles that address therapeutic proposals for 5-FU-induced intestinal mucositis.

Articles were searched from January to March 2021. Access to federated communities was made available through the CAPES journal portal to obtain the full articles. The descriptors used were: “intestinal mucositis”, “intestinal mucositis AND 5-Fluorouracil” and “intestinal mucositis AND 5-fluorouracil AND treatment”, and 5390 articles were found. Review studies, the duplication of data or titles, abstracts that did not meet the inclusion criteria and lack of pertinent information were all excluded, totaling 32 articles for analysis in this review.

For the discussion of the data and interpretation of the research, the approach to the theme was considered; the year of publication; the article available in full. The presentation of the articles found, both included and excluded, as well as their applied distribution, is shown in the PRISMA flow (Figure 1).

Results and Discussion

By searching the databases cited, the search found 5390 studies in the period, but 5358 were rejected, as they did not meet the inclusion criteria. Thus, a total of 32 publications were selected on the subject, covering the treatment of 5-FU-induced intestinal mucositis in the period highlighted in this study (Table 01), which were accessed and read for subsequent selection of the characteristics that incorporated the research.

Regarding intestinal mucositis, this review showed there is no effective clinical treatment for this condition, since no articles were found pointing to clinical evidence. On the other hand, several types of animal research are being developed, which generally evaluate the effectiveness of a certain substance, based on the discovery of the pharmacological effect of these substances on the fundamental mechanisms involved in the pathogenesis of mucositis, such as the generation of reactive oxygen species (ROS), pro-inflammatory cytokines, mediators of apoptosis, microbiota alteration and damage and rupture of the epithelial barrier.

Figure 1. Prisma Flow diagram for include / exclude and data process
### Table 1. Main aspects of studies on intestinal mucositis, in chronological order, in articles published from 2015 to 2019.

<table>
<thead>
<tr>
<th>№</th>
<th>Type of study</th>
<th>Periodical</th>
<th>Place of study</th>
<th>Main aspects</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Experimental</td>
<td>PlosOne</td>
<td>Taipei</td>
<td><em>Lactobacillus casei</em>variety <em>rhamnosus</em> (Lcr35) and <em>Bifidobacterium bifidum</em> (LaBi) probiotics may improve chemotherapy-induced intestinal mucositis.</td>
<td>Yeung et al., 2015</td>
</tr>
<tr>
<td>2</td>
<td>Experimental</td>
<td>Plos One</td>
<td>Kyoto</td>
<td>Saireto, a traditional Japanese herbal medicine, attenuates intestinal mucositis induced by 5-FU.</td>
<td>Kato et al., 2015</td>
</tr>
<tr>
<td>3</td>
<td>Experimental</td>
<td>Biol. Pharm. Bull.</td>
<td>Gyeonggi-Do</td>
<td>Rebamipid promotes various mechanisms of mucosal protection and attenuates mucosal lesion induced by 5-FU.</td>
<td>Kim et al., 2015</td>
</tr>
<tr>
<td>4</td>
<td>Experimental</td>
<td>Tox. reports</td>
<td>Goiania</td>
<td>The results showed Mucoadhesive formulation of <em>Bidens pilosa</em> L. to be safe and efficient against 5-FU induced intestinal mucositis in mice.</td>
<td>DE ÁVILA et al., 2015</td>
</tr>
<tr>
<td>5</td>
<td>Experimental</td>
<td>Lipids Health Dis</td>
<td>Belo Horizonte</td>
<td>Dietary supplementation with omega-3 fatty acid decreases the mucosal damage caused by 5-FU-induced mucositis.</td>
<td>GENEROSO et al., 2015</td>
</tr>
<tr>
<td>6</td>
<td>Experimental</td>
<td>Hum ExpToxicol;</td>
<td>Shenyang</td>
<td>Bu-Zhong-Yi-Qi decoction (BZYQD) inhibits 5-FU-induced intestinal mucositis, and this effect may be due to the reduction in apoptosis and necrosis in intestinal mucosal epithelia via the suppression of inflammatory cytokine upregulation.</td>
<td>GOU et al., 2016</td>
</tr>
<tr>
<td>7</td>
<td>Experimental</td>
<td>Eur Revfor Med and Pharma Scien</td>
<td>Cluj-Napoca</td>
<td>Pretreatment with rifaximin for three consecutive days proved efficient in preventing degenerative mucosal lesions induced by 5-FU in the duodenum, jejunum and colon.</td>
<td>Ciobanu et al., 2016</td>
</tr>
<tr>
<td>8</td>
<td>Experimental</td>
<td>World Jour Gastroent</td>
<td>Adelaide</td>
<td>Low dose rhubarb extract improves selected parameters of mucosal integrity and reduces ileal inflammation, manifesting from 5-FU-induced intestinal mucositis.</td>
<td>Bajic et al., 2016</td>
</tr>
<tr>
<td>9</td>
<td>Experimental</td>
<td>ToxicologyReports</td>
<td>Goiânia</td>
<td>Curcuminoid mucoadhesive formulation (MFC) from <em>Curcuma longa</em> L. presented therapeutic potential for the treatment of intestinal mucositis in mice.</td>
<td>Dos Santos Filho et al., 2016</td>
</tr>
<tr>
<td>11</td>
<td>Experimental</td>
<td>ToxicologyReports</td>
<td>Goiânia</td>
<td>A mucoadhesive formulation containing <em>Bidens pilosa</em> L. and <em>Curcuma longa</em> L. was able to protect mice from 5-FU-induced intestinal injury.</td>
<td>Bastos et al., 2015</td>
</tr>
<tr>
<td>12</td>
<td>Experimental</td>
<td>Jour Funct Foods</td>
<td>Hamamatsu</td>
<td>Arabinoxylan supplementation effectively improved intestinal mucositis and myelosuppression.</td>
<td>Song et al., 2016</td>
</tr>
<tr>
<td>13</td>
<td>Experimental</td>
<td>Clin and Exp Pharm and Phy</td>
<td>Kyoto</td>
<td>Probiotic <em>Bifidobacterium bifidum</em> G9-1 attenuates 5-fluorouracil-induced intestinal mucositis in mice via suppression of dysbiosis-related secondary inflammatory responses</td>
<td>Kato et al., 2017</td>
</tr>
<tr>
<td>No.</td>
<td>Type</td>
<td>Journal/Source</td>
<td>City</td>
<td>Summary</td>
<td></td>
</tr>
<tr>
<td>-----</td>
<td>------</td>
<td>----------------</td>
<td>------</td>
<td>---------</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>Experimental</td>
<td>Journal of physiology and pharmac</td>
<td>Kyoto</td>
<td>Lafutidine, a histamine H2 receptor antagonist, can attenuate 5-FU-induced intestinal mucositis, most likely by increasing mucus production via activation of sensory afferent neurons.</td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>Experimental</td>
<td>Front Pharmacol</td>
<td>Kunming</td>
<td>Amomum volatilum (VOA) and its main active constituent, bornyl acetate (BA), attenuates 5-fluorouracil-induced intestinal mucositis in mice.</td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>Experimental</td>
<td>Nutrition</td>
<td>Dalian</td>
<td>Treatment with a probiotic mixture, (Bifidobacterium breve, Lactobacillus acidophilus, L. casei and Streptococcus thermophilus) ameliorated 5-FU-induced intestinal mucositis.</td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>Experimental</td>
<td>Letters in Applied Microbiology</td>
<td>Seoul</td>
<td>Mulberry leaf extract fermented with Lactobacillus acidophilus A4 ameliorates 5-fluorouracil-induced intestinal mucositis in rats.</td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>Experimental</td>
<td>Nutrition</td>
<td>Tucumán</td>
<td>The riboflavin-overproducing strain Lactobacillus plantarum CRL2130 could be useful to prevent mucositis during cancer treatments and would not affect the primary treatment.</td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>Experimental</td>
<td>Rev Col Bras Cir</td>
<td>Natal</td>
<td>Simvastatin attenuated gastric and intestinal mucositis related to 5-FU therapeutics in animal model.</td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>Experimental</td>
<td>Journal of Functional Foods</td>
<td>Belo Horizonte</td>
<td>The results showed fruit oligosaccharide (FOS) supplementation presented protective effects on intestinal barrier function.</td>
<td></td>
</tr>
<tr>
<td>21</td>
<td>Experimental</td>
<td>Front Microbiol</td>
<td>Belo Horizonte</td>
<td>Whey Protein Isolate-Supplemented maximizes the anti-inflammatory effects of Lactobacillus casei BL23, in preventing mucositis induced by 5-Fluorouracil in BALB/c mice.</td>
<td></td>
</tr>
<tr>
<td>22</td>
<td>Experimental</td>
<td>Journal of MedFood</td>
<td>Guangzhou</td>
<td>Enteral Nutrition Supplemented with Crassostrea hongkongensis Polysaccharides can ameliorate 5-FU-induced intestinal mucositis.</td>
<td></td>
</tr>
<tr>
<td>23</td>
<td>Experimental</td>
<td>Phytomedicine</td>
<td>Tianjin</td>
<td>Aquilariae Lignum Resinatum protected against 5-FU-induced intestinal mucositis in mice.</td>
<td></td>
</tr>
<tr>
<td>24</td>
<td>Experimental</td>
<td>Journal of Functional Foods</td>
<td>Belo Horizonte</td>
<td>The work demonstrates the protective effect of Lactobacillus delbrueckii subsp. lactis CIDCA 133 on the damage of the intestinal mucosa in a murine model of inflammation induced by a chemotherapeutic drug.</td>
<td></td>
</tr>
<tr>
<td>25</td>
<td>Experimental</td>
<td>EurJourofPharmac</td>
<td>Islamabad</td>
<td>Diadzein could inhibit 5-FU-induced intestinal mucositis.</td>
<td></td>
</tr>
<tr>
<td>26</td>
<td>Experimental</td>
<td>Pharmaceuticals</td>
<td>Fortaleza</td>
<td>Cashew Gum (Anacardium occidentale L.) prevented 5-FU-induced intestinal mucositis.</td>
<td></td>
</tr>
<tr>
<td>27</td>
<td>Experimental</td>
<td>Food &amp; Function</td>
<td>Beijing</td>
<td>Carboxymethyl pachyman could regulate the ecological balance of the intestinal flora and reduce colon injuries induced by 5-FU in CT26 tumour-bearing mice</td>
<td></td>
</tr>
</tbody>
</table>
The articles presented in this review bring into their methodological scope the evaluation of products of natural origin, nutritional supplementation/probiotics or drugs that are redirected to the treatment of intestinal mucositis.

**Probiotics and Nutritional Supplements**

We found 12 articles evaluating the effect of probiotics and other nutritional supplements on intestinal mucositis (IM) induced by 5-FU. The articles found in this review separately evaluated four types of probiotics, namely: *Lactobacillus delbrueckii*, *Lactobacillus casei* variety *rhamnosus*, *Bifidobacterium bifidum* and *Lactobacillus acidophilus*.

In addition to the combination of *L. casei* BL23 and/or *Propionibacterium freudenreichii* 138 + Whey Protein isolate, as well as a mixture of probiotics, namely: *Bifidobacterium breve, Lactobacillus acidophilus* 7, as well as a mixture of probiotics or drugs that are redirected to the treatment of intestinal mucositis.

**Therapeutic Proposals That Improve Morphological Changes Of 5-Fluorouracil-Induced Intestinal Mucositis:**

We found 12 articles evaluating the effect of probiotics and other nutritional supplements on intestinal mucositis (IM) induced by 5-FU. The articles found in this review separately evaluated four types of probiotics, namely: *Lactobacillus delbrueckii* 10, *Lactobacillus casei* variety *rhamnosus*, *Bifidobacterium bifidum* and *Lactobacillus acidophilus* 26. In addition to the combination of *L. casei* BL23 and/or *Propionibacterium freudenreichii* 138 + Whey Protein isolate, as well as a mixture of probiotics from four strains (*Bifidobacterium breve, Lactobacillus acidophilus, L. casei* e *Streptococcus thermophilus*) 24, and the combination of mulberry leaf extract with *Lactobacillus acidophilus* 25.

The study of De Jesus et al. 26 demonstrated that *L. Plantarum* CRL2130 attenuated the pathologic changes induced by 5-FU in mice such as body weight loss, diarrhea, shortening of villus height, and elevated production of interleukin 10, an anti-inflammatory cytokine. In vitro assays using Caco-2 cells showed the effectiveness of 5-FU was not affected by *L. Plantarum* CRL2130 and that this strain exerted an inhibitory mechanism against oxidative stress.

Other researchers showed the mulberry leaf extract fermented with *Lactobacillus acidophilus* A4 has ably ameliorated the weight loss and the histopathologic parameters. The treatments also stimulated MUC2 and MUC5AC gene expression and mucin production and reduced IL-1β expression and MPO level. These results suggest fermented mulberry leaf extract may provide synergistic therapeutic benefits of both probiotics and natural plant extracts in the prevention of 5-fluorouracil-induced mucositis 25.

Yeung and collaborators 33 found after oral *Lactobacillus acidophilus* and *Bifidobacterium bifidum* administrations, the diarrhea scores decreased, repair of damage in jejunal villi was observed and the probiotics treatment suppressed this upregulation the TNF-α, IL-1β, and IL-6. Huang et al. 32 also demonstrated that *Lactobacillus casei* variety *rhamnosus* or the mixture that *Lactobacillus acidiphilus* and *Bifidobacterium bifidum* could significantly inhibit serum cytokines TNF-α, IL-1β, IFNγ, IL-6, IL-4, IL-10, and IL-17, and that it could improve diarrhea with jejunal mucosa repair.

In the study by Cordeiro et al. 27, it was observed probiotic beverages fermented by *L. casei* BL23 and *P. freudenreichii* 138 were able to decrease 5-FU-induced intestinal inflammation, preserving mucosal integrity, and reducing weight loss and preserving the number of goblet cells. The addition of Whey Protein-Isoolate was found to improve the beneficial effects of *L. casei*...
BL23, but not P. freudenreichii.

The treatment with a probiotic mixture (Bifidobacterium breve, Lactobacillus acidophilus, L. casei e Streptococcus thermophilus) ameliorated 5-FU–induced intestinal mucosal injury, preserved histopathological changes, and mucus reduced the proinflammatory cytokines (IL-4, IL-6, TNF-α) and neutrophil infiltration, but not reduced the bodyweight loss. Moreover, the treatment reduced the intestinal permeability and reestablishment of intestinal microbial homeostasis and alteration of the toll-like receptors 2 and 4 (TLR2/TLR4) signaling pathway a defense system against microorganisms.

The exact mechanisms by which probiotics exert their beneficial effects remain unknown. However, from the findings in this review, it was observed probiotics appear to attenuate the severity of mouse-induced intestinal mucositis by 5-FU treatment by inhibiting inflammatory parameters (cytokines and neutrophils), improving intestinal permeability and microbiota balance.

According to Van et al., the microbiota can influence mucositis development and severity through at least five different mechanisms. These include influencing the inflammatory response, intestinal permeability, mucin layer composition, epithelial repair, resistance to harmful stimuli, and the intestinal immune system, all of which can have important implications for both mucositis severity and host health.

Prebiotics is nondigestible food ingredients that selectively stimulate the growth or activity of bacteria in the colon, that beneficially affect the host. In this sense, Galdino et al., demonstrated that fructo-oligosaccharides (prebiotic) were also capable of reduced inflammatory infiltrate (MPO) and improved intestinal permeability, and preserved intestinal mucosa. Carvalho et al. also found that fructo-oligosaccharides effects included maintenance of tight junctions expression with a reduction in the inflammatory infiltrate and histological score and improvement in short-chain fatty acids production. These effects contributed to the restoration and preservation of mucosal architecture.

In turn, Generoso et al. showed omega-3 supplementation less weight loss decreased intestinal permeability and bacterial translocation besides preserving the mucosal integrity and reduced number of apoptotic cells the ileum mucosa. Cai et al. also observed the enteral nutrition supplemented with Crassostrea hongkongensis Polysaccharides showed to positively influence in intestinal mucositis, since, ameliorate atrophy of the villi with fewer goblet cells, reducing pro-inflammatory cytokine secretion (IL-2), releasing anti-inflammatory cytokines (IL-10), inhibiting inflammatory pathways, improving the barrier function, preventing epithelial cell apoptosis and eliminating pathogenic bacteria.

In summary, Table 2 shows the synthesis of effective probiotics and supplements in the studies.

### Plant extracts and substances isolated

We found 16 articles in which the authors investigated the protective effect of products of natural origin, plant extracts, or even plant-isolated substances. A common feature of this group is that the investigated substances had a traditional use and/or already had evidence of antioxidant and anti-inflammatory activity. The main parameters included histological evaluation, body weight, inflammatory and oxidative parameter evaluation, apoptosis evaluation, and investigation of the probable way in which the substances acted.

Atiq et al. demonstrated that diadzein, an isoflavone in nature and isolated from plants such as soybean, was able to inhibit 5-FU-induced intestinal mucositis. It did this by preventing leukopenia, decreasing morphometric and histopathological changes, inhibiting oxidative stress with the equilibrium of GSH, GTS, MDA, catalase and nitrite concentrations, as well as the preservation of goblet cells’ equilibrium in the inflammatory parameters (COX-2, TNF-α, p-JNK, IL-6, IL-1β).

### Table 2. Concentration of probiotics and supplements used in preclinical studies for intestinal mucositis induced for 5-Fluorouracil

<table>
<thead>
<tr>
<th>Probiotic/Nutritional supplement</th>
<th>Concentration</th>
</tr>
</thead>
<tbody>
<tr>
<td>L. delbrueckii subsp. lactis CIDCA 133 fermented milk</td>
<td>7.5 x 10⁷ CFU/ml</td>
</tr>
<tr>
<td>Mulberry leaf extract fermented with L. acidophilus A4</td>
<td>100 µg/ml and 10⁹ CFU/ml(A4)</td>
</tr>
<tr>
<td>L. plantarum</td>
<td>10⁸ CFU/ml</td>
</tr>
<tr>
<td>L. casei and P. freudenreichii 138 with Whey Protein</td>
<td>10⁸ CFU/ml</td>
</tr>
<tr>
<td>Probiotic mixture (B. breve, L. acidophilus, L. casei, and S. thermophilus).</td>
<td>10⁷ CFU</td>
</tr>
<tr>
<td>L. casei variety rhamnosus and Lacidophilus with B. bifidum</td>
<td>10⁷ CFU</td>
</tr>
<tr>
<td>B. bifidum</td>
<td>10⁹ CFU</td>
</tr>
<tr>
<td>Fructo-oligosaccharides</td>
<td>240 mg (6% of total kg)</td>
</tr>
<tr>
<td>Crassostrea hongkongensis Polysaccharides</td>
<td>0,0195 mg / mL</td>
</tr>
<tr>
<td>Dietary supplementation with omega-3 fatty acid</td>
<td>3.5 % fish oil</td>
</tr>
</tbody>
</table>
Therapeutic Proposals That Improve Morphological Changes Of 5-Fluorouracil-Induced Intestinal Mucositis: a Review of the Literature

Barbosa MLL et al.

M Miranda et al.\textsuperscript{11} showed that Cashew Gum (a polysaccharide) was able to reverse weight loss, prevent histopathological changes, decrease the number of mast cells, and reduce leukopenia. Moreover, Cashew Gum also reduced oxidative stress, the expression of COX-2 and IL-1β, and the concentration of MPO.

Bu-Zhong-Yi-Qi's decoction (BZYQD), a water extract of Chinese traditional herbal medicine, was able to inhibit morphological signs of intestinal damage, including shortened villi height. Crypt destruction, apoptosis, and necrosis in intestinal mucosal epithelia were also reversed, accompanied by reduced neutrophil infiltration, nitrite levels, and inflammatory factors (TNFa and IL1β) and increased levels of reduced glutathione\textsuperscript{37}.

Aquilariiae Lignum Resinatum, also a traditional Chinese medicine treatment, improved food-intake and reduced injury of the intestinal mucosa, relieved body weight loss and severe diarrhea through up-regulating the expression of proliferating cell nuclear antigen (PCNA) and inhibiting the levels of cyclooxygenase-2 (COX-2) and tumor necrosis factor-α (TNF-α) in ileum segments\textsuperscript{20}.

Kato et al.\textsuperscript{14}, found Saireito, a Japanese traditional herbal medicine, reduced the increase in apoptotic cells on the intestinal crypts, such as the expression of TNF-α and IL-1β mRNA, body weight loss, diarrhea, and potentially reduced tumor growth. In contrast, the administration of Saireto did not alter the anti-proliferative action of 5-FU in the intestinal crypts.

A mucoadhesive containing curcuminoids from Curcuma longa L. showed significant results towards body weight loss, as all the animals treated had body weight loss reduced. Besides that, curcuminoids demonstrated a protective effect on 5-FU-induced intestinal mucositis, not only by reducing the shortening in the duodenal villi height and crypt depth but also by decreasing histological severity scores. Besides, there was less apoptosis on intestinal cells, greater expression of Ki-67, and significantly diminished tissue oxidative stress and free radical production\textsuperscript{8}.

De Ávila et al.\textsuperscript{9} also used a mucoadhesive to treat 5-FU induced mucositis, made of Bidens pilosa L. (Asteraceae). Most of the elements investigated, such as body weight, morphometric and histological analysis, the evaluation of the small intestine, and expression of Ki-67, Bax, MPO, and MDA, had significant results in the groups treated compared with the 5-FU group. Another study investigated the effect of a mucoadhesive containing not only Bidens Pilosa L. (Asteraceae) but also Curcuma longa L. (Zingiberaceae). It protected against 5-FU intestinal damage regarding the size of the crypts and villi and weight loss, promoted the increase of blood cells, and recovered the proliferative activity of the intestinal tissue in the animals with mucositis, due to the significant expression of Ki-67, Bax, and Bel-2\textsuperscript{20}.

Bajic et al.\textsuperscript{2} showed rhubarb, Rheum spp, a perennial herbaceous plant with anthraquinones as its main active ingredient, in the form of a relatively low-dose aqueous extract, offers partial protection to the distal intestinal mucosa against tissue damage and inflammation associated with 5-FU induced intestinal mucositis.

Wei-Chang-An is a traditional Chinese pharmaceutical preparation with potential anti-inflammatory action that reduced body weight loss, alleviating severe diarrhea and gastric emptying (GE), and gastrointestinal transit. Further evaluations also validated that Wei-Chang-An promoted intestinal mucosal recovery, evaluated enterocyte proliferation activity, maintained tight junction integrity, and improved inflammatory disorders\textsuperscript{8}.

Song et al.\textsuperscript{20} demonstrated that Arabinoyxlan has immunomodulatory effects through activation of NK cells, dendritic cells, modulating cytokines and tumor cell-induced apoptosis, and suppressed the side effects associated with 5-FU in mice, alleviating oxidative stress and myelosuppression.

Xiang et al.\textsuperscript{33} found that Andrographolide, a labdane diterpenoid, significantly ameliorated 5-FU-induced weight loss, diarrhea, and apoptosis. Besides, Andrographolide markedly downregulated the 5-FU-induced protein expression of caspase8/3, Bax, and the phosphorylation of p38.

Rutin, a flavonoid, prevents intestinal inflammation by inhibiting MDA, MPO, COX-2, oxidative stress and mastocytosis. This flavonoid also stimulates increased villi and increased the GSH concentrations\textsuperscript{32}. The authors propose that the action mechanism is the inhibition of COX-2. This hypothesis agrees with Miranda et al.\textsuperscript{12}, in a study that demonstrated that troxerutin, a flavonoid derived from rutin, also reduced the effects of intestinal mucositis for reduction of COX-2.

Zhang et al.\textsuperscript{23} demonstrated that volatile oil of A. villosum and bornyl acetate prevented diarrhea, reversed weight loss, and reduced food intake. Besides, it improved histopathological changes in intestinal mucositis, perhaps due to a reduction in inflammatory parameters, decreased p38 MAPK and caspase-3 proteins, and improved the function of the intestinal mucosal barrier. Bornyl acetate also contributed to the regulation of intestinal microbiota balance.

Interestingly, Chen et al.\textsuperscript{34} demonstrated that the likely mechanism by which Berberine (isoquinoline alkaloid) would exert its protective effect on intestinal mucositis would be through the regulation of the intestinal microbiota. Wang et al.\textsuperscript{30} also demonstrated that this mechanism is important for intestinal mucositis. The authors found that Carboxymethyl pachyman (a polysaccharide) could regulate the ecological balance of the intestinal flora and reduce colon injuries induced by 5-FU.

In this article, we observed that the researchers
mainly investigated a wide variety of plants of traditional use, as well as polysaccharides and flavonoids with antioxidant and anti-inflammatory action.

**Drug Repurposing**

In this review, we also found 4 papers that evaluated the effect of drugs that were originally recommended for other pathologies, but which have been suggested as an alternative for the treatment of 5-FU-induced intestinal mucositis. Medeiros et al.\textsuperscript{27} investigated the effect of simvastatin, a drug used to treat high cholesterol.

The authors found simvastatin reduced weight loss, improved histopathological scores, and decreased expression of proinflammatory cytokines (TNF-α, IL-1β, and IL-6). The authors did not investigate the likely mechanism of action related to improvement observed with drug use; however, the study suggests that a likely action in COX-2 could explain the decrease in cytokines.

Another study found that Lafutidine, an antiacid histamine H2 receptor antagonist with mucosal protective properties via sensory afferent neurons showed protective effects in intestinal mucositis-induced 5-FU. Lafutidine was able to reduce diarrhea, histopathological changes, MPO, TNF-α, IL-1β, and apoptosis, but did not decrease weight loss. However, it is worth noting that Lafutidine increased mucus production (number of goblet cells) via activation of sensory afferent neurons\textsuperscript{22}.

Kim et al.\textsuperscript{15} demonstrated that rebamipide, an anti-gastric ulcer and gastritis agent, showed clinical and histological mucosal protective effects and also preventative effects against apoptosis. It decreased inflammatory cytokines (TGF-β1, TNF-α) and macrophage accumulation, preserved the concentration of GSH, and suppressed iNOS expression and diarrhea.

In an experimental study, Ciobanu et al.\textsuperscript{5} proposed a different approach for microbiota modulation, by using rifaximin, an antibiotic. Rifaximin reduced histopathological scores, preserved goblet cell number, and decreased the expression of TLR. The authors explained that the gut microbiota plays a key role in this phase, through the activation of TRL, and then can also up-regulate NFκB.

Thus, we can observe that drugs with a different mechanism of action showed some effects in 5-FU-induced intestinal mucositis.

**Conclusion**

From this review, it was possible to recognize a considerable number of studies involving intestinal mucositis. The information gathered demonstrates that substances isolated from plants, probiotics with emphasis on those of the genus *Lactobacillus*, nutritional supplements, and even repurposed drugs were evaluated in connection with 5-FU-induced intestinal mucositis, and these showed a protective effect on several morphological parameters (Figure 2). However, no results were observed with research with humans. Thus, although there are many studies, the treatment of intestinal mucositis remains a gap in science and there is a need for future research with clinical evaluation on the subject.
References

20. Wang, C; Yang S.; Gao, L; Wang,L; Gao. L. Carboxymethyl pachyman (CMP) reduces intestinal mucositis and regulates the intestinal microflora in 5-fluorouracil-treated CT26 tumour-bearing mice. Food and function 2018; 9, 2695.
Mini Curriculum and Author’s Contribution

1. Maria Lucianny Lima Barbosa -MsC; PhD student. Contribution: Effective scientific and intellectual participation for the study; data acquisition; data interpretation; preparation and draft of the manuscript; critical review and final approval. ORCID: 0000-0003-1652-6544.

2. Lorena Lopes Brito-Miss. Nutrition student; Contribution: Data acquisition; data interpretation; preparation and draft of the manuscript. ORCID: 0000-0001-6313-1794.

3. Bárbara Barbosa Pires-Miss. Medical student; Contribution: Data acquisition; data interpretation; preparation and draft of the manuscript. ORCID: 0000-0003-2269-0690

4. Joselane Maria da Silva-B.Sc. Nutritionist; Contribution: Data acquisition; data interpretation; preparation and draft of the manuscript. ORCID: 0000-0002-1111-659X

5. João Antônio Leal de Miranda; PhD. Contribution: Effective scientific and intellectual participation for the study; critical review and final approval. ORCID: 0000-0002-0273-4169

6. Gilberto Santos Cerqueira; PhD. Contribution: Guiding professor; Design of the study; critical review and final approval. ORCID: 0000-0001-6717-3772

Received: April 19, 2021
Accepted: April 30, 2021

Corresponding author
Maria Lucianny Lima Barbosa
E-mail: lucianny.barbosa@alu.ufc.br